Meeting News

Patient, clinical characteristics impact recovery time after dialysis

WASHINGTON — Data presented at ASN Kidney Week determined specific demographic and clinical variables were associated with the time patients needed to recover after hemodialysis treatments.

“Hemodialysis is lifesaving, yet can associate with symptoms (eg, nausea, cramping and fatigue),” Yue Jiao, MD, of Fresenius Medical Care North America, and colleagues wrote in a poster abstract. “Dialysis recovery time (DRT) surveys capture the perceived time after [hemodialysis] HD to return to performing regular activities. We characterized the profiles and determinants of DRT in incident HD treated at a large dialysis organization (LDO) in the United States.”

Researchers examined data from 98,616 patients who completed a dialysis recovery time survey within the first 180 days of hemodialysis initiation (mean age, 62.6 years; 64.7% used a catheter). The survey, which is a component of the kidney disease quality of life questionnaire, asked patients how long it takes them to be able to return to “normal activities” after a dialysis treatment (less than 30 minutes to more than 4 hours).

Of those surveyed, 19.1% reported recovery time of less than 1 hour, while 22.9% reported a recovery time of more than 4 hours.

Researchers found longer recovery times were associated with various factors, including catheter use; lower albumin, sodium and intact parathyroid hormone levels; lower Kt/V, ultrafiltration volume by body weight, ultrafiltration rates and treatment frequency.

They noted that treatment time, interdialytic weight gain and phosphate levels did not appear to contribute to longer recovery time.

“More than 20% of incident HD patients report a DRT [greater than] 4 hours,” the researchers concluded. “Patient-centered strategies to optimize the HD therapy need to be tested and may have potential to improve how patients feel from HD and enhance their quality of life.” – by Melissa J. Webb

Reference:

Jiao Y, et al. Abstract TH-PO595. Presented at: ASN Kidney Week; Nov. 7-10, 2019; Washington, D.C.

Disclosure: Jiao reports being an employee of Fresenius Medical Care North America.

WASHINGTON — Data presented at ASN Kidney Week determined specific demographic and clinical variables were associated with the time patients needed to recover after hemodialysis treatments.

“Hemodialysis is lifesaving, yet can associate with symptoms (eg, nausea, cramping and fatigue),” Yue Jiao, MD, of Fresenius Medical Care North America, and colleagues wrote in a poster abstract. “Dialysis recovery time (DRT) surveys capture the perceived time after [hemodialysis] HD to return to performing regular activities. We characterized the profiles and determinants of DRT in incident HD treated at a large dialysis organization (LDO) in the United States.”

Researchers examined data from 98,616 patients who completed a dialysis recovery time survey within the first 180 days of hemodialysis initiation (mean age, 62.6 years; 64.7% used a catheter). The survey, which is a component of the kidney disease quality of life questionnaire, asked patients how long it takes them to be able to return to “normal activities” after a dialysis treatment (less than 30 minutes to more than 4 hours).

Of those surveyed, 19.1% reported recovery time of less than 1 hour, while 22.9% reported a recovery time of more than 4 hours.

Researchers found longer recovery times were associated with various factors, including catheter use; lower albumin, sodium and intact parathyroid hormone levels; lower Kt/V, ultrafiltration volume by body weight, ultrafiltration rates and treatment frequency.

They noted that treatment time, interdialytic weight gain and phosphate levels did not appear to contribute to longer recovery time.

“More than 20% of incident HD patients report a DRT [greater than] 4 hours,” the researchers concluded. “Patient-centered strategies to optimize the HD therapy need to be tested and may have potential to improve how patients feel from HD and enhance their quality of life.” – by Melissa J. Webb

Reference:

Jiao Y, et al. Abstract TH-PO595. Presented at: ASN Kidney Week; Nov. 7-10, 2019; Washington, D.C.

Disclosure: Jiao reports being an employee of Fresenius Medical Care North America.

    See more from American Society of Nephrology Annual Meeting